Monocytes with Oncogenic Mutation  JAK2 V617F  as a Tool for Studies of the Pathogenic Mechanisms of Myelofibrosis

A. A. Silyutina; I. I. Gin; S. S. Prikhod’ko; S. V. Zhuk; P. A. Butylin; A. Yu. Zaritskii

doi:10.1007/s10517-018-4033-x

Monocytes with Oncogenic Mutation JAK2 V617F as a Tool for Studies of the Pathogenic Mechanisms of Myelofibrosis

Авторлар: Silyutina A.¹, Gin I.¹, Prikhod’ko S.¹, Zhuk S.¹, Butylin P.¹, Zaritskii A.¹
Мекемелер:
1. Research Laboratory of Oncohematology, Institute of Hematology, V. A. Almazov National Medical Research Centre
Шығарылым: Том 164, № 4 (2018)
Беттер: 569-575
Бөлім: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
URL: https://journals.rcsi.science/0007-4888/article/view/239750
DOI: https://doi.org/10.1007/s10517-018-4033-x
ID: 239750

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Тек жазылушылар үшін

Аннотация
Авторлар туралы
Әдебиет тізімі
Статистика

Аннотация

We analyzed previously generated stable monocyte-derived cell line carrying mutation JAK2 V617F. Evaluation of the expression of pro- and antifibrotic factors revealed changes in the production of MMPs and their inhibitors, growth factors, galectin-3, and pentraxin 3 in cells carrying mutation JAK2 in comparison with control non-modified cells.